Pre-admission acetylsalicylic acid therapy and impact on in-hospital outcome in COVID-19 patients: The ASA-CARE study
Articolo
Data di Pubblicazione:
2021
Citazione:
Pre-admission acetylsalicylic acid therapy and impact on in-hospital outcome in COVID-19 patients: The ASA-CARE study / A. Sisinni, L. Rossi, A. Battista, E. Poletti, F. Battista, R.A. Battista, A. Malagoli, A. Biagi, A. Zanni, C. Sticozzi, G. Comastri, M.M. Marrocco-Trischitta, A. Monello, A. Margonato, F. Bandera, P. Vergara, M. Guazzi, C. Godino. - In: INTERNATIONAL JOURNAL OF CARDIOLOGY. - ISSN 0167-5273. - 344:(2021), pp. 240-245. [10.1016/j.ijcard.2021.09.058]
Abstract:
Background: Patients with coronavirus disease 2019 (COVID-19) exhibit high thrombotic risk. The evidence on a potential independent prognostic role of antiplatelet treatment in those patients is limited. The aim of the study was to evaluate the prognostic impact of pre-admission low-dose acetylsalicylic acid (ASA) in a wide series of hospitalized patients with COVID-19. Methods: This cohort study included 984 COVID-19 patients stratified according to ASA intake before hospitalization: ASA+ (n = 253) and ASA− (n = 731). Patients were included in ASA+ group if they received it daily in the 7 days before admission. 213 (83%) were on ASA 100 mg daily. Primary endpoint was a composite of in-hospital death and/or need for respiratory support upgrade, secondary endpoints were in-hospital death and need for respiratory support upgrade. Results: Mean age was 72 [62; 81] with 69% of male patients. ASA+ patients were significantly older, with higher prevalence of comorbidities. No significant differences regarding the degree of respiratory dysfunction were observed. At 30-day Kaplan-Meier analysis, ASA+ patients had higher survival free from the primary endpoint and need for respiratory support upgrade, conversely in-hospital death did not significantly differ between groups. At multivariate analysis ASA intake was independently associated with a lower probability of reaching primary endpoint (HR 0.697, 95% C.I. 0.525–0.924; p = 0.012). Conclusions: In COVID-19 patients undergoing hospitalization, pre-admission treatment with ASA is associated with better in-hospital outcome, mainly driven by less respiratory support upgrade.
Tipologia IRIS:
01 - Articolo su periodico
Keywords:
Acetylsalicylic acid; COVID-19; Platelet aggregation inhibitors; SARS-CoV-2; Thrombosis; Aged; Cohort Studies; Hospital Mortality; Hospitalization; Hospitals; Humans; Male; SARS-CoV-2; Aspirin; COVID-19
Elenco autori:
A. Sisinni, L. Rossi, A. Battista, E. Poletti, F. Battista, R.A. Battista, A. Malagoli, A. Biagi, A. Zanni, C. Sticozzi, G. Comastri, M.M. Marrocco-Trischitta, A. Monello, A. Margonato, F. Bandera, P. Vergara, M. Guazzi, C. Godino
Link alla scheda completa: